Skip to main content
Genome&Company logo

Genome&Company — Investor Relations & Filings

Ticker · 314130 ISIN · KR7314130006 KO Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2024-06-05 Report Publication Anno…
Country KR South Korea
Listing KO 314130

About Genome&Company

http://genomecom.co.kr/

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling and details of an upcoming Investor Relations (IR) meeting (기업설명회). It provides the date, location, target audience, and purpose of the meeting. Since this is an announcement of an event rather than the presentation materials themselves, and it does not fit into other specific categories like earnings releases or financial reports, it is classified as a Regulatory Filing (RNS) as it serves as a general corporate disclosure.
2024-06-05 Korean
투자판단관련주요경영사항 (GENA-111 기반 항체-약물접합체ADC 개발 및 상업화 기술이전 계약 체결)
M&A Activity Classification · 100% confidence The document is a regulatory filing from a Korean company (Genome & Company) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details a specific technology transfer agreement (licensing deal) for an ADC platform with a Swiss company, Debiopharm. This type of disclosure regarding material business contracts, licensing, and technology partnerships falls under the category of general regulatory filings as it does not fit into specific categories like M&A (which usually implies corporate mergers/acquisitions of entities) or other specialized reports.
2024-06-03 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (a press conference/briefing) to be held by Genome & Company. It provides details such as the date, location, purpose, and participants. Since it is an announcement of an event rather than a comprehensive presentation deck or a financial report, and it fits the criteria for a regulatory announcement regarding corporate activities, it is classified as a Regulatory Filing (RNS).
2024-06-03 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, location, target audience, and the purpose of the meeting (company status and value enhancement). Since this is an announcement of an event rather than the presentation slides themselves, and it is a short regulatory notice, it falls under the category of a regulatory filing announcement.
2024-06-03 Korean
기타경영사항(자율공시) (전환우선주의 보통주 전환청구)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Genome & Company regarding the conversion of convertible preferred shares into common shares. This involves a change in the company's capital structure and share count. According to the provided definitions, 'Share Issue/Capital Change' (SHA) covers announcements regarding new share issues or capital changes, which aligns with the conversion of preferred shares into common shares and the resulting change in capital stock.
2024-06-03 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the first quarter of 2024, filed by Genome & Company. It contains detailed corporate information, management discussion, financial data, and business operations, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.